# NEW UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 45753-DIV

Total Pages in this Submission 369

# TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

ansmitted herewith	for filing under 35 U.S.C.	111(a) and 37 C.F.F	R. 1.53(b) is a new	utility patent application	n for an
Potion entitled:					

		TEIN	N COUPLED RECEPTOR PROTEIN, PRODUCTION, AND USE THEREOF						
and in	vente	ed by	:						
Sh	uji H	INUN	MA, Masaki HOSOYA, Ryo FUJII, Tetsuya OHTAKI, Shoji FUKUSUMI and Kazuhiro OHGI						
If a C	ONT	NUA	ATION APPLICATION, check appropriate box and supply the requisite information:						
	onti	nuat	ion  Divisional Continuation-in-part (CIP) of prior application No.: 08/513,974						
Enclo	sed a	are:	Application Elements						
4	<b>\sigma</b>	C:lim							
1.	X	FIIIN	ng fee as calculated and transmitted as described below						
2.	X	Spe	cification having pages and including the following:						
	a.	X	Descriptive Title of the Invention						
	b.		Cross References to Related Applications (if applicable)						
	C.		Statement Regarding Federally-sponsored Research/Development (if applicable)						
	d.		Reference to Microfiche Appendix (if applicable)						
	e.	X	Background of the Invention						
	f.	X	Brief Summary of the Invention						
	g.	X	Brief Description of the Drawings (if drawings filed)						
	h.	X	Detailed Description						
	i.	X	Claim(s) as Classified Below						
	j.	X	Abstract of the Disclosure						
3.	×	Drav	wing(s) (when necessary as prescribed by 35 USC 113)						
	a.		Formal						
	b.	X	Informal						
			Number of Sheets						

# delleo e e e e e e

# NEW UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 45753-DIV

Total Pages in this Submission 369

# **Application Elements (Continued)**

4.	X	Oath or Declaration							
	a.	☐ Newly executed (original or copy) ☐ Unexecuted							
	b.	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)							
	C.	☑ With Power of Attorney ☐ Without Power of Attorney							
5.	X	Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.							
6.		Computer Program in Microfiche (Appendix)							
7.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)							
	a.	☐ Paper Copy							
	b.	☐ Computer Readable Copy (identical to computer copy)							
	C.	☐ Statement Verifying Identical Paper and Computer Readable Copy							
		Accompanying Application Parts							
8.		Assignment Papers (cover sheet & document(s))							
9.		37 CFR 3.73(B) Statement (when there is an assignee)							
10.		English Translation Document (if applicable)							
11.		Information Disclosure Statement/PTO-1449   Copies of IDS Citations							
12.		Preliminary Amendment							
13.	X	Acknowledgment postcard							
14.	×	Certificate of Mailing							
		☐ First Class ☒ Express Mail (Specify Label No.): TB562667875US							
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)							

# DODESTE DELLOPO

# NEW UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 45753-DIV

Total Pages in this Submission 369

$\boxtimes$	Additional Enclosures (please identify below):						
	Transfer of Sequence Listing						

## Fee Calculation and Transmittal

## **CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra		Rate	Fee		
Total Claims		- 20 =	0	x	\$22.00	\$0.00		
Indep. Claims - 3 =			0	x	\$82.00	\$0.00		
Multiple Depender	Multiple Dependent Claims (check if applicable)							
					BASIC FEE	\$790.00		
OTHER FEE (spe	OTHER FEE (specify purpose)							
					TOTAL FILING FEE	\$790.00		

$\boxtimes$	۸ ۵	heck	in	the	am	oun	t of

to cover the filing fee is enclosed.

- The Commissioner is hereby authorized to charge and credit Deposit Account No. 04-1105 as described below. A duplicate copy of this sheet is enclosed.
  - ☐ Charge the amount of

as filing fee.

- ☑ Credit any overpayment.
- ☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: //- 3- 5 と

Signature

David S. Resnick (Reg. No. 34,235)
Dike, Bronstein, Roberts & Cushman, LLP

130 Water Street Boston, MA 02109

CC:

Ō

o

45753-DIV Attorney's Docket No.

PATENT

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

S. Hinuma, et al.

Serial No.: not yet assigned

Group No.:

Filed: herewith

Examiner:

For: G PROTEIN COUPLED RECEPTOR PROTEIN

PRODUCTION, AND USE THEREOF

Commissioner of Patents and Trademarks Washington, D.C. 20231

# **EXPRESS MAIL CERTIFICATE**

"Express Mail" label number \_ TB562667875US March 11, 1997 Date of Deposit

I hereby certify that the following attached paper or fee New Utility Patent Application Transmittal; 277 pages of specification; 79 sheets of drawings; Transfer of Sequence Listing; Preliminary Amendment; copy of executed Declaration and Power of Attorney from parent. Check for \$790.00.

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Noreen Buckley

(typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

NOTE: Each paper must have its own certificate and the "Express Mail" label number as a part thereof or attached thereto. When, as here, the certification is presented on a separate sheet, that sheet must (1) be signed and (2) fully identify and be securely attached to the paper or fee it accompanies. Identification should include the serial number and filing date of the application as well as the type of paper being filed, e.g. complete application, specification and drawings, responses to rejection or refusal, notice of appeal, etc. If the serial number of the application is not known, the identification should include at least the name of the inventor(s) and the title of the invention.

NOTE: The label number need not be placed on each page. It should, however, be placed on the first page of each separate document, such as, a new application, amendment, assignment, and transmittal letter for a fee, along with the certificate of mailing by "Express Mail." Although the label number may be on checks, such a practice is not required. In order not to deface formal drawings it is suggested that the label number be placed on the back of each formal drawing or the drawings be accompanied by a set of informal drawings on which the label number is placed.

(Express Mail Certificate [8-3])



Docket No.: 45753-V

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXAMINER: Not yet assigned

APPLICANT: K. Nakao, et al.

SERIAL NO.: not yet assigned

GROUP:

FILED: herewith

FOR: G PROTEIN COUPLED RECEPTOR PROTEIN, PRODUCTION AND USE THEREOF

**Assitant Commissioner for Patents** 

Washington, D.C. 20231

Sir:

# TRANSFER OF SEQUENCE LISTING

The computer readable form in this application is identical with that filed in U.S.S.N. 08/513,974, filed September 14, 1995. In accordance with 37 CFR 1.821(e), please use the computer readable form filed September 16, 1997, in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally-filed specification of the instant application.

In accordance with 37 CFR §§1.821-1.825, I hereby state that the content of the paper, computer-readable copies of the sequence listing submitted in accordance with 37 CFR §1.821(c) and (e) on September 16, 1997, respectively, are the same. I hereby state that the submission, filed in accordance with 37 CFR §1.821(g), does not introduce new matter.

Respectfully submitted,

DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP

Date: 11-3-98

Ō

David S. Resnick (Reg. No.: 34235)

Attorney for Applicant

130 Water Street

Boston, Massachusetts 02109

(617) 523-3400